Table 1 Baseline characteristics of the LUAD patients.
From: TEDC2 correlated with prognosis and immune microenvironment in lung adenocarcinoma
Characteristics | N | (%) |
|---|---|---|
Age | ||
 > 65 | 261 | 50.6 |
 ≤ 65 | 255 | 49.4 |
Gender | ||
 Male | 249 | 46.5 |
 Female | 286 | 53.5 |
Smoking history | ||
 Yes | 446 | 85.6 |
 No | 75 | 14.4 |
T stage | ||
 T1 | 175 | 32.9 |
 T2 | 289 | 54.3 |
 T3 | 49 | 9.2 |
 T4 | 19 | 3.6 |
N stage | ||
 N0 | 348 | 67.1 |
 N1 | 95 | 18.3 |
 N2 | 74 | 14.3 |
 N3 | 2 | 0.4 |
M stage | ||
 M0 | 361 | 93.5 |
 M1 | 25 | 6.5 |
Pathologic stage | ||
 Stage I | 294 | 55.8 |
 Stage II | 123 | 23.3 |
 Stage III | 84 | 15.9 |
 Stage IV | 26 | 4.9 |
TEDC2 expression | ||
 High | 268 | 50.1 |
 Low | 267 | 49.9 |
